Updated:
UroGen Pharma
UroGen Pharma was founded in 2004 in Israel, originally as TheraCoat, with a technology platform for optimizing drug delivery to the urinary tract.
UroGen Pharma
UroGen Pharma was founded in 2004 in Israel, originally as TheraCoat, with a technology platform for optimizing drug delivery to the urinary tract. The firm relocated its headquarters to Princeton, New Jersey, and in 2017 appointed Liz Barrett — a veteran of Novartis, Pfizer, and Cephalon — as CEO. Barrett brought the commercial experience of launching oncology blockbusters to a company that had yet to bring a product to market. UroGen's strategy concentrates on uro-oncology with a proprietary reverse-thermal hydrogel technology, RTGel. This liquid formulation is instilled into the bladder or upper urinary tract as a cold liquid, then warms to body temperature to form a semisolid gel that slowly releases chemotherapy directly at the tumor site. The flagship asset, Jelmyto (mitomycin) for pyelocalyceal solution, received FDA approval in 2020 for adult patients with low-grade upper tract urothelial cancer — a niche where the standard of care previously meant radical nephroureterectomy, or kidney removal. The pipeline extends the RTGel platform to next-generation mitomycin formulations (UGN-102) for low-grade non-muscle invasive bladder cancer, advancing toward a potential FDA submission. UroGen commercializes Jelmyto through a specialty sales force in the US, and maintains a research and development footprint in Ra'anana, Israel. As of early 2024, UroGen trades on Nasdaq under the ticker UROY with a market capitalization near $500 million. The firm reported full-year 2023 Jelmyto net product revenues of approximately $81 million. In February 2024, the company completed enrollment in the Phase 3 ENVISION trial of UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer, with topline data indicating a complete response rate of 79.6% at three months (per the firm, February 2024). The intent is to file a New Drug Application with the FDA, which would represent the first FDA-approved non-surgical treatment for a broader bladder cancer population. UroGen's structural differentiator is its singular focus on a therapeutic model that has no direct pharmaceutical competitor: localized chemoablation for a cancer type that urologists have historically treated with radical surgery. The company's long-duration patent estate on the RTGel platform and its concentrated commercial infrastructure in genitourinary oncology create a narrow but defensible position. If UGN-102 secures approval, UroGen will control the non-surgical standard of care across the upper and lower urinary tract.
General information
Firm type
Asset Manager
Year founded
2004
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Princeton
Corporate office
Princeton, NJ, United States
Additional offices
Ra'anana, Israel
Principals
Liz Barrett
President and Chief Executive Officer
Sector focus
Frequently asked questions
Who runs UroGen Pharma, and what is her background?
Liz Barrett has served as President and Chief Executive Officer since 2019, after joining the company in 2017 as Chief Commercial Officer. Prior to UroGen, she was Global President of Oncology at Novartis, overseeing a multi-billion-dollar portfolio that included targeted therapies and immuno-oncology agents. She also held senior commercial roles at Pfizer and Cephalon. Her experience centers on launching and scaling oncology franchises in competitive US and global markets.
What does UroGen actually sell, and is it on the market?
UroGen's sole commercial product is Jelmyto (mitomycin for pyelocalyceal solution), approved by the FDA in April 2020. It treats adult patients with low-grade upper tract urothelial carcinoma. Jelmyto is administered via catheter as a liquid, then transforms into a gel that bathes the tumor site for sustained drug release. Full-year 2023 net product revenues were approximately $81 million.
What is UroGen's most important pipeline asset?
UGN-102 (mitomycin) is an extended-release formulation delivered via the same RTGel platform, targeting low-grade intermediate-risk non-muscle invasive bladder cancer. The Phase 3 ENVISION trial met its primary endpoint, showing a 79.6% complete response rate at three months post-treatment. The company intends to submit a New Drug Application to the FDA based on these data, potentially creating the first non-surgical approved treatment for this broader patient population.
Where does UroGen conduct research and development?
Research and development is anchored in Ra'anana, Israel, where UroGen was originally founded. The corporate headquarters and commercial operations are based in Princeton, New Jersey. The dual structure reflects the company's origin as a platform technology spinout and its subsequent pivot to a US-centric commercial biotech focused on genitourinary cancers.
How does UroGen's gel technology actually work?
RTGel is a reverse-thermal hydrogel. It is liquid when cold and congeals into a semisolid gel at body temperature. UroGen formulates standard chemotherapeutic agents — currently mitomycin — within this gel. After a urologist instills the mixture through a catheter, the gel adheres to the bladder or upper urinary tract lining and slowly releases the drug over several hours, maximizing tumor exposure while limiting systemic absorption.
Is UroGen profitable?
No. UroGen has not reached profitability. Full-year 2023 reported a net loss, typical of a commercial-stage biotech investing in a specialty sales force and funding multiple Phase 3 registrational trials simultaneously. The investment thesis often cited by analysts (per public filings and equity research) centers on the revenue expansion potential of broadening the RTGel platform beyond the niche Jelmyto indication.
What makes UroGen structurally different from other oncology biotechs?
UroGen is the only company with an FDA-approved product that allows direct, localized chemoablation of upper tract urothelial carcinoma. Most oncology developers aim for systemic therapies. UroGen's model is device-like in its local-administration dependency, requiring an established urology sales force and specific procedural reimbursement codes. The narrow uro-oncology focus means the firm's fate is tied to a handful of indications with no direct pharmaceutical competitors, but also limited pipeline diversification.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: